Jonathan Northrup

Jonathan Northrup is a seasoned executive and entrepreneur in the biotechnology and pharmaceutical industries. He currently serves as a Board Member and Advisor at Vasculonics, a position he has held since September 2020.1

Current Roles

Northrup is also the CEO and Co-founder of Stingray Therapeutics, an immune oncology company he established in June 2018.12 At Stingray Therapeutics, he is focused on developing innovative therapies in the field of immune oncology.1

Other Board Positions

In addition to his roles at Vasculonics and Stingray Therapeutics, Northrup holds several other board positions:

• Board Member at Iterion Therapeutics (since June 2018)
• Board Member and Co-founder at Salarius Pharmaceuticals (since January 2012)1

Previous Experience

Northrup's career in the pharmaceutical and biotechnology industries spans several decades. Some of his previous positions include:

• CEO, Board Member, and Co-founder of Beta Cat Pharmaceuticals (March 2011 - June 2018)
• COO at Jubilant Innovation (January 2007 - March 2011)
• CEO & Founder of Horizon Biotechnologies (2004 - 2006)
• VP of Business Development & Strategy at Eli Lilly (1996 - 2004)1

Education

Northrup holds an MBA from The Wharton School of Business, which he obtained between 1974 and 1976. He also has a Bachelor of Arts (B.A.) from Northwestern University, earned between 1970 and 1974.1

Professional Certification

In 2010, Northrup was awarded the Certified Licensing Professional (CLP) designation by the Licensing Executive Society, recognizing his expertise in business development and licensing.1